Will NASP transform gout care in 2026? Sobi’s biologic therapy heads for FDA decision

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for NASP, a novel uricase-based therapy developed by Swedish Orphan Biovitrum AB (STO: SOBI), commonly known as Sobi. The candidate drug, Nanoencapsulated Sirolimus plus Pegadricase (NASP), is being evaluated for patients with uncontrolled gout—a condition affecting more than 200,000 individuals in the U.S. for whom conventional therapies fail to lower serum uric acid (sUA) levels adequately.

The regulatory milestone sets a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2026, placing Sobi’s NASP in contention to become one of the first targeted immunomodulating treatments addressing this high unmet medical need. The BLA submission includes pivotal data from the DISSOLVE I and DISSOLVE II Phase 3 trials, which met their primary efficacy endpoints.

As analysts begin to model the commercial opportunity of NASP in the United States, institutional sentiment appears cautiously optimistic, citing the drug’s differentiated dual-action profile and consistent clinical response across dose cohorts.

What makes Sobi’s NASP a potentially transformative therapy for uncontrolled gout in 2025?

The investigational therapy NASP, formerly known as SEL-212, represents a mechanistic innovation in the treatment of uncontrolled gout. Sobi describes the therapy as a fixed-dose, once-every-four-weeks infusion that combines nanoencapsulated sirolimus with pegadricase, a pegylated uricase.

The sirolimus component functions by suppressing the formation of anti-drug antibodies (ADAs), a common limitation in the use of biologics—especially uricase-based therapies. Meanwhile, pegadricase breaks down uric acid enzymatically, directly reducing systemic levels of sUA. This combination aims to address both the root cause of hyperuricemia and the immune system’s tendency to neutralize biologic interventions.

Dr. Lydia Abad-Franch, Sobi’s Chief Medical Officer, emphasized that the therapy’s dual mechanism could help patients experiencing chronic inflammation, tophus buildup, and frequent flares—hallmarks of refractory gout. She noted that current oral urate-lowering therapies fall short for this patient population, which continues to suffer from comorbidities and diminished quality of life.

What were the key findings from the DISSOLVE I and II Phase 3 trials supporting the FDA submission?

The BLA submission is underpinned by data from two randomized, placebo-controlled Phase 3 trials—DISSOLVE I and DISSOLVE II—designed to evaluate both the safety and efficacy of NASP in adults with uncontrolled gout. In both studies, patients were administered either a high or low dose of NASP over a six-month period.

The trials met their primary endpoints, with pooled response rates of 51% and 43% in the high- and low-dose arms, respectively. The benchmark was achieving and maintaining serum uric acid levels under 6 mg/dL for at least 80% of the sixth month. This biochemical target is widely accepted as a key marker in gout control.

Secondary endpoints showed promising outcomes as well. NASP led to rapid and sustained reductions in sUA following the first dose. Patients also experienced meaningful clinical benefits such as tophus resolution, a decline in flare frequency, and improvements in patient-reported quality-of-life metrics.

Importantly, the safety profile of NASP was consistent across both dosing regimens, with the drug being generally well tolerated throughout the trial period. No unexpected adverse events were reported, strengthening the drug’s case for eventual approval.

Why is NASP’s FDA fast track designation important for Sobi’s regulatory and commercial timeline?

In May 2024, the FDA granted Fast Track designation to NASP based on its potential to address a serious and life-altering condition with limited current treatment options. This designation offers several regulatory advantages, including more frequent engagement with the FDA and the possibility of a rolling submission.

The acceptance of the BLA with a June 2026 PDUFA date marks the most advanced stage of development yet for NASP. If approved, the drug could position Sobi as a key player in the niche but underserved segment of refractory gout, potentially unlocking a new revenue stream in the United States.

The Swedish biopharmaceutical company has long focused on rare diseases, and NASP aligns well with that strategic mission. Institutional analysts suggest that successful commercialization in the U.S. could pave the way for global expansion and lifecycle management strategies, including post-marketing studies and real-world data collection.

How significant is the market opportunity for therapies targeting uncontrolled gout in the United States?

Gout affects over 8.3 million people in the U.S., making it the most prevalent form of inflammatory arthritis. Of this population, around 200,000 individuals suffer from uncontrolled gout—patients who continue to exhibit elevated uric acid levels despite standard oral therapies.

Uncontrolled gout is not just painful—it is also medically complex. Chronic hyperuricemia can lead to comorbidities involving cardiovascular, renal, and metabolic systems. Tophi can form around joints and tissues, resulting in visible deformities, restricted mobility, and, in some cases, irreversible damage.

As a result, this patient segment represents a high-value target for biopharmaceutical innovation. Market observers note that few therapies are currently approved specifically for this cohort, and even fewer offer long-term immunotolerant efficacy.

Should NASP secure regulatory approval, it would enter a relatively uncongested field with minimal direct competition, at least in the near term. Analysts predict that payer receptivity will hinge on real-world effectiveness, durability of response, and overall cost-effectiveness relative to downstream hospitalizations or surgical interventions.

What role could NASP play in reducing anti-drug antibody formation in biologic therapies?

One of the longstanding challenges in biologic medicine—especially enzyme replacement and immune-modulating therapies—is the formation of anti-drug antibodies (ADAs). These immune responses can reduce a biologic’s effectiveness over time and contribute to side effects or even treatment discontinuation.

Sobi’s approach with NASP is noteworthy because it proactively incorporates tolerogenic nanoencapsulation of sirolimus. This strategy aims to induce a more regulated immune response, potentially delaying or preventing ADA formation. If this mechanism proves successful in the real world, it could represent a platform innovation applicable beyond gout to other biologic-driven disease areas.

In this sense, NASP is not just a single-product bet—it may also serve as a proof-of-concept for Sobi’s broader ambitions in immunomodulatory therapies. This strategic optionality has not been lost on institutional investors, who are watching closely to see if the sirolimus-based immune conditioning holds up under commercial scrutiny.

What does the BLA acceptance mean for Sobi’s growth strategy and investor sentiment in 2025?

With revenues reaching SEK 26 billion in 2024 and approximately 1,900 employees across five continents, Swedish Orphan Biovitrum AB has positioned itself as a mid-sized global rare disease player. The FDA’s acceptance of NASP’s BLA further validates Sobi’s R&D pipeline and its commitment to addressing overlooked therapeutic segments.

Investor sentiment has generally been positive, particularly given NASP’s Fast Track designation and the strength of the DISSOLVE trials. That said, the company must navigate complex commercial launch dynamics, including infusion logistics, specialist training, and reimbursement negotiations.

Analysts are expected to track several key milestones over the next 12–18 months. These include any additional FDA feedback ahead of the PDUFA date, possible European filing intentions, and interim updates on real-world access infrastructure in the U.S. healthcare market.

With the market largely pricing in an aggressive push into North America, execution risk remains a critical variable. However, if Sobi can deliver on regulatory and market-entry fronts, NASP could materially alter the company’s revenue mix and investor profile by late 2026.

What is the outlook for NASP and the future of gout therapy innovation heading into 2026?

The June 2026 PDUFA date puts NASP on a high-stakes regulatory clock. If approved, it could open the door for a new generation of biologics that not only treat but also prevent the immune system from sabotaging therapeutic success. This dual-action mechanism sets NASP apart in a field historically dominated by oral small molecules with variable efficacy in severe cases.

The broader gout therapy landscape is also evolving. As the understanding of systemic uric acid regulation deepens, future treatments may adopt multi-pronged approaches similar to NASP. Moreover, with digital monitoring tools and real-world evidence frameworks gaining traction, companies like Sobi could leverage longitudinal data to support future indication expansions or dosing refinements.

Analysts believe that if Sobi executes effectively, it could become a bellwether for how smaller European biotechs scale in the U.S. market—not through blockbuster gambits but through focused, data-backed, high-need therapies.